Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMD 273066 with Cyclophosphamide in Recurrent Ovarian Carcinoma
NCT00408967Phase 2Withdrawn
- Sponsor
- EMD Serono
- Start
- Dec 2006
- Primary completion
- May 2008
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of tucotuzumab celmoleukin in ovarian carcinoma, sponsored by EMD Serono. Planned start Dec 2006; status: withdrawn.
02
Drugs
tucotuzumab celmoleukin
03
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT00408967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408967.